Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma
Epistemonikos ID: 4703d46eaf14b53361f9a29f9e2d712d37f83002
First added on: May 09, 2024